nodes	percent_of_prediction	percent_of_DWPC	metapath
Octreotide—Asthenia—Teniposide—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Octreotide—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Octreotide—Malaise—Bleomycin—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Octreotide—Pruritus—Teniposide—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Octreotide—Arrhythmia—Carmustine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Octreotide—Cystitis—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Octreotide—Cardiac disorder—Vincristine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Octreotide—Alopecia—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Octreotide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Octreotide—Mental disorder—Carmustine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Octreotide—Vaginal infection—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Octreotide—Malnutrition—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Octreotide—Erythema—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Octreotide—Cough—Bleomycin—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Octreotide—Diarrhoea—Teniposide—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Octreotide—Chest pain—Bleomycin—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Octreotide—Myalgia—Bleomycin—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Octreotide—Alopecia—Vincristine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Octreotide—Back pain—Carmustine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Octreotide—Discomfort—Bleomycin—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Octreotide—Mental disorder—Vincristine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Octreotide—Urine output increased—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Octreotide—Bladder pain—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Octreotide—Mouth ulceration—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Octreotide—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Octreotide—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Octreotide—Alopecia—Mitoxantrone—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Octreotide—Vision blurred—Carmustine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Octreotide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Octreotide—Tremor—Carmustine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Octreotide—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Octreotide—Oedema—Bleomycin—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Octreotide—Erythema—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Octreotide—Infection—Bleomycin—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Octreotide—Anaemia—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Octreotide—Back pain—Vincristine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Octreotide—Vomiting—Teniposide—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Octreotide—Agitation—Carmustine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Octreotide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Octreotide—Asthenia—Fludarabine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Octreotide—Rash—Teniposide—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Octreotide—Dermatitis—Teniposide—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Octreotide—Headache—Teniposide—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Octreotide—Pruritus—Fludarabine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Octreotide—Back pain—Mitoxantrone—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Octreotide—Anorexia—Bleomycin—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Octreotide—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Octreotide—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Octreotide—Anaemia—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Octreotide—Agitation—Vincristine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Octreotide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Octreotide—Polyuria—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Octreotide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Octreotide—Convulsion—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Octreotide—Hypertension—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Octreotide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Octreotide—Nausea—Teniposide—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Octreotide—Anaemia—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Octreotide—Vertigo—Vincristine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Octreotide—Myalgia—Carmustine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Octreotide—Chest pain—Carmustine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Octreotide—Anxiety—Carmustine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Octreotide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Octreotide—Malaise—Mitoxantrone—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Octreotide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Octreotide—Convulsion—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Octreotide—Hypertension—Vincristine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Octreotide—Oedema—Carmustine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Octreotide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Octreotide—Myalgia—Vincristine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Octreotide—Visual disturbance—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Octreotide—Cough—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Octreotide—Infection—Carmustine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Octreotide—Vomiting—Fludarabine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Octreotide—Convulsion—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Octreotide—Rash—Fludarabine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Octreotide—Dermatitis—Fludarabine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Octreotide—Hypertension—Mitoxantrone—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Octreotide—Pain—Bleomycin—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Octreotide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Octreotide—Headache—Fludarabine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Octreotide—Tachycardia—Carmustine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Octreotide—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Octreotide—Myalgia—Mitoxantrone—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Octreotide—Chest pain—Mitoxantrone—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Octreotide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Octreotide—Anxiety—Mitoxantrone—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Octreotide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Octreotide—Oedema—Vincristine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Octreotide—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Octreotide—Anorexia—Carmustine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Octreotide—Infection—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Octreotide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Octreotide—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Octreotide—Nervous system disorder—Vincristine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Octreotide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Octreotide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Octreotide—Oedema—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Octreotide—Nausea—Fludarabine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Octreotide—Infection—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Octreotide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Octreotide—Shock—Mitoxantrone—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Octreotide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Octreotide—Urticaria—Bleomycin—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Octreotide—Anorexia—Vincristine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Octreotide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Octreotide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Octreotide—Insomnia—Carmustine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Octreotide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Octreotide—Irritability—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Octreotide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Octreotide—Paraesthesia—Carmustine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Octreotide—Dyspnoea—Carmustine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Octreotide—Somnolence—Carmustine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Octreotide—Anorexia—Mitoxantrone—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Octreotide—Decreased appetite—Carmustine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Octreotide—Insomnia—Vincristine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Octreotide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Octreotide—Paraesthesia—Vincristine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Octreotide—Constipation—Carmustine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Octreotide—Pain—Carmustine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Octreotide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Octreotide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000995	0.000995	CcSEcCtD
Octreotide—Decreased appetite—Vincristine—lymphatic system cancer	0.000989	0.000989	CcSEcCtD
Octreotide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000988	0.000988	CcSEcCtD
Octreotide—Somnolence—Mitoxantrone—lymphatic system cancer	0.000985	0.000985	CcSEcCtD
Octreotide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000982	0.000982	CcSEcCtD
Octreotide—Feeling abnormal—Carmustine—lymphatic system cancer	0.000982	0.000982	CcSEcCtD
Octreotide—Fatigue—Vincristine—lymphatic system cancer	0.000981	0.000981	CcSEcCtD
Octreotide—Asthenia—Bleomycin—lymphatic system cancer	0.00098	0.00098	CcSEcCtD
Octreotide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000975	0.000975	CcSEcCtD
Octreotide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000975	0.000975	CcSEcCtD
Octreotide—Pain—Vincristine—lymphatic system cancer	0.000973	0.000973	CcSEcCtD
Octreotide—Constipation—Vincristine—lymphatic system cancer	0.000973	0.000973	CcSEcCtD
Octreotide—Asthma—Methotrexate—lymphatic system cancer	0.000971	0.000971	CcSEcCtD
Octreotide—Pruritus—Bleomycin—lymphatic system cancer	0.000966	0.000966	CcSEcCtD
Octreotide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000963	0.000963	CcSEcCtD
Octreotide—Fatigue—Mitoxantrone—lymphatic system cancer	0.000955	0.000955	CcSEcCtD
Octreotide—Pancreatitis—Methotrexate—lymphatic system cancer	0.000952	0.000952	CcSEcCtD
Octreotide—Pain—Mitoxantrone—lymphatic system cancer	0.000947	0.000947	CcSEcCtD
Octreotide—Constipation—Mitoxantrone—lymphatic system cancer	0.000947	0.000947	CcSEcCtD
Octreotide—Abdominal pain—Carmustine—lymphatic system cancer	0.000942	0.000942	CcSEcCtD
Octreotide—Body temperature increased—Carmustine—lymphatic system cancer	0.000942	0.000942	CcSEcCtD
Octreotide—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000931	0.000931	CcSEcCtD
Octreotide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00093	0.00093	CcSEcCtD
Octreotide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000913	0.000913	CcSEcCtD
Octreotide—Dysuria—Methotrexate—lymphatic system cancer	0.000908	0.000908	CcSEcCtD
Octreotide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000906	0.000906	CcSEcCtD
Octreotide—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000902	0.000902	CcSEcCtD
Octreotide—Body temperature increased—Vincristine—lymphatic system cancer	0.000899	0.000899	CcSEcCtD
Octreotide—Abdominal pain—Vincristine—lymphatic system cancer	0.000899	0.000899	CcSEcCtD
Octreotide—Urticaria—Mitoxantrone—lymphatic system cancer	0.00088	0.00088	CcSEcCtD
Octreotide—Hypersensitivity—Carmustine—lymphatic system cancer	0.000878	0.000878	CcSEcCtD
Octreotide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000876	0.000876	CcSEcCtD
Octreotide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000876	0.000876	CcSEcCtD
Octreotide—Pneumonia—Methotrexate—lymphatic system cancer	0.000871	0.000871	CcSEcCtD
Octreotide—Vomiting—Bleomycin—lymphatic system cancer	0.000868	0.000868	CcSEcCtD
Octreotide—Drowsiness—Methotrexate—lymphatic system cancer	0.000866	0.000866	CcSEcCtD
Octreotide—Depression—Methotrexate—lymphatic system cancer	0.000863	0.000863	CcSEcCtD
Octreotide—Rash—Bleomycin—lymphatic system cancer	0.000861	0.000861	CcSEcCtD
Octreotide—Dermatitis—Bleomycin—lymphatic system cancer	0.00086	0.00086	CcSEcCtD
Octreotide—Asthenia—Carmustine—lymphatic system cancer	0.000855	0.000855	CcSEcCtD
Octreotide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000841	0.000841	CcSEcCtD
Octreotide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000838	0.000838	CcSEcCtD
Octreotide—Haematuria—Methotrexate—lymphatic system cancer	0.000825	0.000825	CcSEcCtD
Octreotide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000819	0.000819	CcSEcCtD
Octreotide—Epistaxis—Methotrexate—lymphatic system cancer	0.000816	0.000816	CcSEcCtD
Octreotide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000816	0.000816	CcSEcCtD
Octreotide—Asthenia—Vincristine—lymphatic system cancer	0.000816	0.000816	CcSEcCtD
Octreotide—Diarrhoea—Carmustine—lymphatic system cancer	0.000815	0.000815	CcSEcCtD
Octreotide—Nausea—Bleomycin—lymphatic system cancer	0.000811	0.000811	CcSEcCtD
Octreotide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000795	0.000795	CcSEcCtD
Octreotide—Dizziness—Carmustine—lymphatic system cancer	0.000788	0.000788	CcSEcCtD
Octreotide—Diarrhoea—Vincristine—lymphatic system cancer	0.000778	0.000778	CcSEcCtD
Octreotide—Hepatitis—Methotrexate—lymphatic system cancer	0.000777	0.000777	CcSEcCtD
Octreotide—Pharyngitis—Methotrexate—lymphatic system cancer	0.000771	0.000771	CcSEcCtD
Octreotide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000758	0.000758	CcSEcCtD
Octreotide—Vomiting—Carmustine—lymphatic system cancer	0.000758	0.000758	CcSEcCtD
Octreotide—Dizziness—Vincristine—lymphatic system cancer	0.000752	0.000752	CcSEcCtD
Octreotide—Rash—Carmustine—lymphatic system cancer	0.000751	0.000751	CcSEcCtD
Octreotide—Dermatitis—Carmustine—lymphatic system cancer	0.000751	0.000751	CcSEcCtD
Octreotide—Visual impairment—Methotrexate—lymphatic system cancer	0.000749	0.000749	CcSEcCtD
Octreotide—Headache—Carmustine—lymphatic system cancer	0.000747	0.000747	CcSEcCtD
Octreotide—Tinnitus—Methotrexate—lymphatic system cancer	0.000724	0.000724	CcSEcCtD
Octreotide—Vomiting—Vincristine—lymphatic system cancer	0.000723	0.000723	CcSEcCtD
Octreotide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000721	0.000721	CcSEcCtD
Octreotide—Rash—Vincristine—lymphatic system cancer	0.000717	0.000717	CcSEcCtD
Octreotide—Dermatitis—Vincristine—lymphatic system cancer	0.000717	0.000717	CcSEcCtD
Octreotide—Headache—Vincristine—lymphatic system cancer	0.000713	0.000713	CcSEcCtD
Octreotide—Nausea—Carmustine—lymphatic system cancer	0.000708	0.000708	CcSEcCtD
Octreotide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000704	0.000704	CcSEcCtD
Octreotide—Immune system disorder—Methotrexate—lymphatic system cancer	0.000702	0.000702	CcSEcCtD
Octreotide—Rash—Mitoxantrone—lymphatic system cancer	0.000699	0.000699	CcSEcCtD
Octreotide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000698	0.000698	CcSEcCtD
Octreotide—Headache—Mitoxantrone—lymphatic system cancer	0.000694	0.000694	CcSEcCtD
Octreotide—Alopecia—Methotrexate—lymphatic system cancer	0.000687	0.000687	CcSEcCtD
Octreotide—Mental disorder—Methotrexate—lymphatic system cancer	0.000681	0.000681	CcSEcCtD
Octreotide—Erythema—Methotrexate—lymphatic system cancer	0.000676	0.000676	CcSEcCtD
Octreotide—Malnutrition—Methotrexate—lymphatic system cancer	0.000676	0.000676	CcSEcCtD
Octreotide—Nausea—Vincristine—lymphatic system cancer	0.000676	0.000676	CcSEcCtD
Octreotide—Nausea—Mitoxantrone—lymphatic system cancer	0.000658	0.000658	CcSEcCtD
Octreotide—Back pain—Methotrexate—lymphatic system cancer	0.000654	0.000654	CcSEcCtD
Octreotide—Vision blurred—Methotrexate—lymphatic system cancer	0.000637	0.000637	CcSEcCtD
Octreotide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000628	0.000628	CcSEcCtD
Octreotide—Anaemia—Methotrexate—lymphatic system cancer	0.000625	0.000625	CcSEcCtD
Octreotide—Malaise—Methotrexate—lymphatic system cancer	0.00061	0.00061	CcSEcCtD
Octreotide—Vertigo—Methotrexate—lymphatic system cancer	0.000608	0.000608	CcSEcCtD
Octreotide—Cough—Methotrexate—lymphatic system cancer	0.00059	0.00059	CcSEcCtD
Octreotide—Convulsion—Methotrexate—lymphatic system cancer	0.000586	0.000586	CcSEcCtD
Octreotide—Arthralgia—Methotrexate—lymphatic system cancer	0.000576	0.000576	CcSEcCtD
Octreotide—Myalgia—Methotrexate—lymphatic system cancer	0.000576	0.000576	CcSEcCtD
Octreotide—Chest pain—Methotrexate—lymphatic system cancer	0.000576	0.000576	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000572	0.000572	CcSEcCtD
Octreotide—Discomfort—Methotrexate—lymphatic system cancer	0.000569	0.000569	CcSEcCtD
Octreotide—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000552	0.000552	CcSEcCtD
Octreotide—Infection—Methotrexate—lymphatic system cancer	0.000548	0.000548	CcSEcCtD
Octreotide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000541	0.000541	CcSEcCtD
Octreotide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00054	0.00054	CcSEcCtD
Octreotide—Skin disorder—Methotrexate—lymphatic system cancer	0.000536	0.000536	CcSEcCtD
Octreotide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000534	0.000534	CcSEcCtD
Octreotide—Anorexia—Methotrexate—lymphatic system cancer	0.000526	0.000526	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000503	0.000503	CcSEcCtD
Octreotide—Insomnia—Methotrexate—lymphatic system cancer	0.000499	0.000499	CcSEcCtD
Octreotide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000496	0.000496	CcSEcCtD
Octreotide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000492	0.000492	CcSEcCtD
Octreotide—Somnolence—Methotrexate—lymphatic system cancer	0.000491	0.000491	CcSEcCtD
Octreotide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000486	0.000486	CcSEcCtD
Octreotide—Decreased appetite—Methotrexate—lymphatic system cancer	0.00048	0.00048	CcSEcCtD
Octreotide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000477	0.000477	CcSEcCtD
Octreotide—Fatigue—Methotrexate—lymphatic system cancer	0.000476	0.000476	CcSEcCtD
Octreotide—Pain—Methotrexate—lymphatic system cancer	0.000472	0.000472	CcSEcCtD
Octreotide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000455	0.000455	CcSEcCtD
Octreotide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000451	0.000451	CcSEcCtD
Octreotide—Urticaria—Methotrexate—lymphatic system cancer	0.000439	0.000439	CcSEcCtD
Octreotide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000436	0.000436	CcSEcCtD
Octreotide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000436	0.000436	CcSEcCtD
Octreotide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000407	0.000407	CcSEcCtD
Octreotide—Asthenia—Methotrexate—lymphatic system cancer	0.000396	0.000396	CcSEcCtD
Octreotide—Pruritus—Methotrexate—lymphatic system cancer	0.000391	0.000391	CcSEcCtD
Octreotide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000378	0.000378	CcSEcCtD
Octreotide—Dizziness—Methotrexate—lymphatic system cancer	0.000365	0.000365	CcSEcCtD
Octreotide—Vomiting—Methotrexate—lymphatic system cancer	0.000351	0.000351	CcSEcCtD
Octreotide—Rash—Methotrexate—lymphatic system cancer	0.000348	0.000348	CcSEcCtD
Octreotide—Dermatitis—Methotrexate—lymphatic system cancer	0.000348	0.000348	CcSEcCtD
Octreotide—Headache—Methotrexate—lymphatic system cancer	0.000346	0.000346	CcSEcCtD
Octreotide—Nausea—Methotrexate—lymphatic system cancer	0.000328	0.000328	CcSEcCtD
